AUGX vs. NUTX, AMWL, GNTA, CKPT, CARM, GMTX, CDTX, COCH, LENZ, and NOTV
Should you be buying Augmedix stock or one of its competitors? The main competitors of Augmedix include Nutex Health (NUTX), American Well (AMWL), Genenta Science (GNTA), Checkpoint Therapeutics (CKPT), Carisma Therapeutics (CARM), Gemini Therapeutics (GMTX), Cidara Therapeutics (CDTX), Envoy Medical (COCH), LENZ Therapeutics (LENZ), and Inotiv (NOTV). These companies are all part of the "medical" sector.
Nutex Health (NASDAQ:NUTX) and Augmedix (NASDAQ:AUGX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends, profitability and community ranking.
Nutex Health currently has a consensus target price of $15.00, indicating a potential upside of 2,006.74%. Augmedix has a consensus target price of $3.88, indicating a potential upside of 220.25%. Given Augmedix's stronger consensus rating and higher probable upside, analysts clearly believe Nutex Health is more favorable than Augmedix.
Nutex Health has a net margin of -15.85% compared to Nutex Health's net margin of -41.95%. Augmedix's return on equity of -44.06% beat Nutex Health's return on equity.
Nutex Health received 2 more outperform votes than Augmedix when rated by MarketBeat users. Likewise, 100.00% of users gave Nutex Health an outperform vote while only 50.00% of users gave Augmedix an outperform vote.
Nutex Health has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500. Comparatively, Augmedix has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500.
5.3% of Nutex Health shares are owned by institutional investors. Comparatively, 87.1% of Augmedix shares are owned by institutional investors. 38.5% of Nutex Health shares are owned by insiders. Comparatively, 11.0% of Augmedix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Augmedix has lower revenue, but higher earnings than Nutex Health. Augmedix is trading at a lower price-to-earnings ratio than Nutex Health, indicating that it is currently the more affordable of the two stocks.
In the previous week, Augmedix had 24 more articles in the media than Nutex Health. MarketBeat recorded 26 mentions for Augmedix and 2 mentions for Nutex Health. Augmedix's average media sentiment score of 0.64 beat Nutex Health's score of -0.04 indicating that Nutex Health is being referred to more favorably in the media.
Summary
Nutex Health beats Augmedix on 12 of the 18 factors compared between the two stocks.
Get Augmedix News Delivered to You Automatically
Sign up to receive the latest news and ratings for AUGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AUGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Augmedix Competitors List
Related Companies and Tools
